Epigral (EPIGRAL) Hisse Özeti
Epigral Limited, Hindistan'da ve uluslararası alanda klor-alkali ve ilgili türevleri üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 3/6 |
EPIGRAL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Epigral Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹1,126.00 |
| 52 Haftanın En Yüksek Seviyesi | ₹1,850.00 |
| 52 Haftanın En Düşük Seviyesi | ₹807.00 |
| Beta | 0.19 |
| 1 Aylık Değişim | -3.16% |
| 3 Aylık Değişim | -9.59% |
| 1 Yıllık Değişim | -38.59% |
| 3 Yıllık Değişim | 27.14% |
| 5 Yıllık Değişim | 96.96% |
| Halka arzdan bu yana değişim | 177.03% |
Son Haberler & Güncellemeler
Yeni Anlatı • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?
Anlatı Güncellemesi • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.
Yeni Anlatı • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Recent updates
Yeni Anlatı • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.Yeni Anlatı • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Anlatı Güncellemesi • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Analiz Makalesi • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...Anlatı Güncellemesi • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).Anlatı Güncellemesi • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.Anlatı Güncellemesi • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.Anlatı Güncellemesi • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.Anlatı Güncellemesi • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.Anlatı Güncellemesi • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).Anlatı Güncellemesi • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.Anlatı Güncellemesi • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Analiz Makalesi • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analiz Makalesi • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...Analiz Makalesi • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...Analiz Makalesi • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Analiz Makalesi • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Analiz Makalesi • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...Analiz Makalesi • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analiz Makalesi • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
Yeni Anlatı • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Analiz Makalesi • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...Analiz Makalesi • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...Analiz Makalesi • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Analiz Makalesi • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Hissedar Getirileri
| EPIGRAL | IN Chemicals | IN Pazar | |
|---|---|---|---|
| 7D | 2.6% | -1.4% | -0.2% |
| 1Y | -38.6% | -1.1% | 2.4% |
Getiri vs. Endüstri: EPIGRAL geçen yıl % -1.1 oranında getiri sağlayan Indian Chemicals sektörünün gerisinde kaldı.
Getiri vs Piyasa: EPIGRAL geçen yıl % 2.4 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| EPIGRAL volatility | |
|---|---|
| EPIGRAL Average Weekly Movement | 5.9% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
İstikrarlı Hisse Senedi Fiyatı: EPIGRAL son 3 ayda Indian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: EPIGRAL 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2007 | 1,135 | Kaushal Soparkar | www.epigral.com |
Epigral Limited, Hindistan'da ve uluslararası alanda klor-alkali ve ilgili türevleri üretmekte ve satmaktadır. Şirket, klorlu polivinil klorür (CPVC) reçineleri, epiklorohidrin, klorometanlar değer zinciri, hidrojen peroksit, kostik soda, klor, hidrojen ve kostik potas ürünleri sunmaktadır. Ayrıca zirai kimyasal ürünlerin ticaretini de yapmaktadır.
Epigral Limited Temel Bilgiler Özeti
| EPIGRAL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹48.58b |
| Kazançlar(TTM) | ₹2.71b |
| Gelir(TTM) | ₹26.26b |
17.9x
F/K Oranı1.8x
P/S OranıEPIGRAL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| EPIGRAL gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹26.26b |
| Gelir Maliyeti | ₹16.48b |
| Brüt Kâr | ₹9.78b |
| Diğer Giderler | ₹7.07b |
| Kazançlar | ₹2.71b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 62.82 |
| Brüt Marj | 37.24% |
| Net Kâr Marjı | 10.32% |
| Borç/Özkaynak Oranı | 25.8% |
EPIGRAL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.4%
Mevcut Temettü Verimi6%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/24 08:40 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Epigral Limited 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |